Mortal disseminated intravascular coagulopathy and cutaneous involvement in a COVID-19 positive patient; case report

Abstract

Coronavirus 2019 disease (COVID-19) is a highly deadly disease that causes 77 million cases and 1.6 million deaths worldwide. Many cutaneous manifestations are seen in COVID-19 disease.Cutaneous pathologies such as vascular endothelial damage, prothrombotic conditions, hemorrhagic cutaneous lesions, vasculitis, disseminated intravascular coagulopathy (DIC), ecchymotic skin lesions, purpura, dry gangrene are seen in patients with COVID-19.While our 84-year-old male patient was being treated with COVID-19 pneumonia in the infection ward, DIC developed on the 9th day of his treatment and widespread petechia, purpura, ecchymosis, necrosis, gangrene, bullous skin lesions were observed in his left arm related to this.In our case, we aimed to present a case of DIC that developed as a complication as a result of COVID-19 infection and having a mortal course with cutaneous involvement due to it, to the literature.

Keywords

• DIC
• coronavirus-19
• cutaneous involvement
• infection
• mortality.

References

1. Medicine JHU. Coronavirus resource center. 2020.
2. Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost 2020; 18: 1559-61.
3. Asakura H, Ogawa H. COVID-19-associated coagulopathy and disseminated intravascular coagulation. Int J Hematol 2021; 113: 45-57.
4. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020; 135: 2033-40.
5. Iba T, Levy JH, Thachil J, Wada H, Levi M. The progression from coagulopathy to disseminated intravascular coagulation in representative underlying diseases. Thromb Res 2019; 179: 11-4.
6. Tang N, Li D, Wang X, Sun, Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18: 844-7.
7. Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res 2020; 220: 1-13.
8. Widysanto A, Wahyuni TD, Simanjuntak LH, et al. Ecchymosis in critical coronavirus disease 2019 (COVID-19) patient in Tangerang, Indonesia: a case report. J Thromb Thrombolysis 2020; 1-5.

9. Dolhnikoff M, Duarte-Neto AN, de Almeida Monteiro RA, et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost 2020; 18: 1517-9.
10. Iba T, Levy J. H, Connors J M, et al. The unique characteristics of COVID-19 coagulopathy. Crit Care 2020; 24: 1-8.
11. Takahashi W, Yoneda T, Koba H, et al. Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation. Int J Infect Dis 2020; 102: 529-31.
12. Novara E, Molinaro E, Benedetti I, et al. Severe acute dried gangrene in COVID-19 infection: a case report. Eur Rev Med Pharmacol Sci 2020; 24: 5769-71.